Key result
Higher adiponectin-resistin index linked to ~27% greater risk of metabolic syndrome in T2DM.
Why the study?
Metabolic syndrome commonly increases cardiovascular risk in type 2 diabetes mellitus, prompting investigation of the novel adiponectin-resistin index as a potential predictor of its development.
Observational (n=80)
No
The adiponectin-resistin (AR) index is an independent predictor of metabolic syndrome development in patients with type 2 diabetes, potentially aiding in early metabolic risk stratification.
Answers are grounded in this paper and cite their sources.
May aid metabolic risk stratification in T2DM; hypothesis-generating and requires validation before clinical adoption.
Background and Objectives: This study aimed to investigate the novel adiponectin–resistin (AR) index as a predictor of the development of metabolic syndrome (MetS) in individuals with type 2 diabetes mellitus (T2DM). MetS is common in T2DM and increases cardiovascular risk. Adiponectin and resistin, adipokines with opposing effects on insulin sensitivity and inflammation, make the AR index a potential marker for metabolic risk. Materials and Methods: This prospective observational study included 80 T2DM participants (ages 30–60) from Sarajevo, Bosnia and Herzegovina, over 24 months. The participants were divided into two groups: T2DM with MetS (n = 48) and T2DM without MetS (n = 32). Anthropometric data, biochemical analyses, and serum levels of adiponectin and resistin were measured at baseline and every six months. The AR index was calculated using the formula AR = 1 + log10(R) − 1 + log10(A), where R and A represent resistin and adiponectin concentrations. Logistic regression identified predictors of MetS. Results: T2DM patients who developed MetS showed a significant decline in adiponectin levels (40.19 to 32.49 ng/mL, p = 0.02) and a rise in resistin levels (284.50 to 315.21 pg/mL, p = 0.001). The AR index increased from 2.85 to 2.98 (p = 0.001). The AR index and resistin were independent predictors of MetS after 18 months, with the AR index showing a stronger predictive value (p = 0.007; EXP(B) = 1.265). Conclusions: The AR index is a practical marker for predicting MetS development in T2DM participants, improving metabolic risk stratification. Incorporating it into clinical assessments may enhance early detection and treatment strategies.
No takes yet. Share an insight, caveat, or question.
Fajkić et al. (2024) conducted an observational in Type 2 diabetes mellitus without metabolic syndrome (n=80). Adiponectin-resistin (AR) index was evaluated on Development of metabolic syndrome (MetS) after 18 months (OR 1.265, 95% CI 1.067-1.500, p=0.007). The adiponectin-resistin (AR) index independently predicted the development of metabolic syndrome in patients with type 2 diabetes mellitus over 18 months.
Synapse has enriched 10 related papers. Consider them for comparative context: